Cargando…
Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy
SIMPLE SUMMARY: Research into the immunotherapeutic potential of T cells has predominantly focused on conventional alpha beta (αβ) T cells, which recognize peptide antigens presented by polymorphic major histocompatibility complex (MHC) class I and class II molecules. However, innate-like T cells, s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221220/ https://www.ncbi.nlm.nih.gov/pubmed/35740670 http://dx.doi.org/10.3390/cancers14123005 |
_version_ | 1784732566739222528 |
---|---|
author | Lee, Derek Rosenthal, Carl J. Penn, Natalie E. Dunn, Zachary Spencer Zhou, Yang Yang, Lili |
author_facet | Lee, Derek Rosenthal, Carl J. Penn, Natalie E. Dunn, Zachary Spencer Zhou, Yang Yang, Lili |
author_sort | Lee, Derek |
collection | PubMed |
description | SIMPLE SUMMARY: Research into the immunotherapeutic potential of T cells has predominantly focused on conventional alpha beta (αβ) T cells, which recognize peptide antigens presented by polymorphic major histocompatibility complex (MHC) class I and class II molecules. However, innate-like T cells, such as gamma delta (γδ) T cells, also play important roles in antitumor immunity. Here, we review the current understanding of γδ T cells in antitumor immunity and discuss strategies that could potentially maximize their potential in cancer immunotherapy. ABSTRACT: Gamma delta (γδ) T cells are a minor population of T cells that share adaptive and innate immune properties. In contrast to MHC-restricted alpha beta (αβ) T cells, γδ T cells are activated in an MHC-independent manner, making them ideal candidates for developing allogeneic, off-the-shelf cell-based immunotherapies. As the field of cancer immunotherapy progresses rapidly, different subsets of γδ T cells have been explored. In addition, γδ T cells can be engineered using different gene editing technologies that augment their tumor recognition abilities and antitumor functions. In this review, we outline the unique features of different subsets of human γδ T cells and their antitumor properties. We also summarize the past and the ongoing pre-clinical studies and clinical trials utilizing γδ T cell-based cancer immunotherapy. |
format | Online Article Text |
id | pubmed-9221220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92212202022-06-24 Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy Lee, Derek Rosenthal, Carl J. Penn, Natalie E. Dunn, Zachary Spencer Zhou, Yang Yang, Lili Cancers (Basel) Review SIMPLE SUMMARY: Research into the immunotherapeutic potential of T cells has predominantly focused on conventional alpha beta (αβ) T cells, which recognize peptide antigens presented by polymorphic major histocompatibility complex (MHC) class I and class II molecules. However, innate-like T cells, such as gamma delta (γδ) T cells, also play important roles in antitumor immunity. Here, we review the current understanding of γδ T cells in antitumor immunity and discuss strategies that could potentially maximize their potential in cancer immunotherapy. ABSTRACT: Gamma delta (γδ) T cells are a minor population of T cells that share adaptive and innate immune properties. In contrast to MHC-restricted alpha beta (αβ) T cells, γδ T cells are activated in an MHC-independent manner, making them ideal candidates for developing allogeneic, off-the-shelf cell-based immunotherapies. As the field of cancer immunotherapy progresses rapidly, different subsets of γδ T cells have been explored. In addition, γδ T cells can be engineered using different gene editing technologies that augment their tumor recognition abilities and antitumor functions. In this review, we outline the unique features of different subsets of human γδ T cells and their antitumor properties. We also summarize the past and the ongoing pre-clinical studies and clinical trials utilizing γδ T cell-based cancer immunotherapy. MDPI 2022-06-18 /pmc/articles/PMC9221220/ /pubmed/35740670 http://dx.doi.org/10.3390/cancers14123005 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lee, Derek Rosenthal, Carl J. Penn, Natalie E. Dunn, Zachary Spencer Zhou, Yang Yang, Lili Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy |
title | Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy |
title_full | Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy |
title_fullStr | Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy |
title_full_unstemmed | Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy |
title_short | Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy |
title_sort | human γδ t cell subsets and their clinical applications for cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221220/ https://www.ncbi.nlm.nih.gov/pubmed/35740670 http://dx.doi.org/10.3390/cancers14123005 |
work_keys_str_mv | AT leederek humangdtcellsubsetsandtheirclinicalapplicationsforcancerimmunotherapy AT rosenthalcarlj humangdtcellsubsetsandtheirclinicalapplicationsforcancerimmunotherapy AT pennnataliee humangdtcellsubsetsandtheirclinicalapplicationsforcancerimmunotherapy AT dunnzacharyspencer humangdtcellsubsetsandtheirclinicalapplicationsforcancerimmunotherapy AT zhouyang humangdtcellsubsetsandtheirclinicalapplicationsforcancerimmunotherapy AT yanglili humangdtcellsubsetsandtheirclinicalapplicationsforcancerimmunotherapy |